Artwork

Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

LuTectomy in European Urology

44:50
 
Share
 

Manage episode 381609574 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.
Even better on our YouTube channel
Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.
Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.
Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:

LuTectomy paper in European Urology
LuTectomy Editorial

  continue reading

139 episodes

Artwork
iconShare
 
Manage episode 381609574 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.
Even better on our YouTube channel
Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.
Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.
Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:

LuTectomy paper in European Urology
LuTectomy Editorial

  continue reading

139 episodes

Alle afleveringen

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide